Clinician and patient interviews indicated satisfaction with the items presented to help describe patient symptoms with different lymphomas.
Qualitative and quantitative evidence supporting the use of the European Organization for Research and Treatment of Cancer (EORTC) Item Library revealed little concern among patients and clinicians with using these items to assess symptoms of conditions such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL), according to a recent study published in Journal of Patient-Reported Outcomes.
This analysis included primary qualitative research and secondary exploratory research | Image credit: everythingpossible - stock.adobe.com
Patient-reported outcomes (PROs) can be useful when evaluating new therapies for B-cell malignancies, which are often difficult to treat. However, evaluating benefits in clinical trials with PRO measures requires careful consideration, and little research has been conducted to determine which PRO measures should be used when determining symptoms and if they are useful at all.
The investigators sought to determine which PRO concepts are most important to patients with CLL/SLL or MCL—especially in relation to their symptoms. Additionally, they analyzed if the selection of items from the EORTC Item Library, which offers a possible pathway to constructing symptom impact assessments in cancer, can form a sensible basis for creating a blueprint of disease-related symptoms from these diseases.
The study used mixed methods, comprising a primary qualitative research strand and a secondary exploratory quantitative research strand, the investigators wrote. The qualitative research centered around a literature review, clinician interviews, and patient interviews.
A literature review of qualitative research indicated key symptom concepts, including fatigue, dyspnea, pain, and swelling. Key impact concepts included the functional impacts of walking and doing household chores, and the emotional and social impacts of depression, worry, and social life limitations, the investigators found.
Participating clinicians confirmed the symptoms in each disease area that were identified in the literature review. Additionally, they highlighted symptoms such as lymphadenopathy, those associated with anemia, and systemic symptoms including fever, night sweats, and weight loss.
Moving on to patient interviews, the investigators wrote that 41 participants were enrolled and interviewed in their study (20 participants with CLL/SLL, and 21 with MCL). The participants reported a variety of symptoms and disease-related impacts, and there was a large degree of overlap.
The investigators grouped reported symptoms under 10 domains: swollen lymph nodes, B symptoms, abdominal issues, fatigue, pain, subjective cognitive impairment, other anemia-related issues, thrombocytopenia-related bleeding issues, infection, and other issues. Impact concepts were grouped into 3 domains: physical function, role function, and other impacts such as psychological impact, according to the investigators.
Fatigue was highlighted through patient interviews as one of the most important symptoms, both at diagnosis and over the course of the disease, the investigators found. Fatigue’s persistence and pervasiveness, as well as its impact on everyday life, were emphasized strongly by the patients.
Furthermore, patients described their experiences dealing with B symptoms, which were described across both CLL/SLL and MCL. They described experiencing these symptoms successively, separately, or in combination, the investigators found.
A quantitative analysis was also conducted. The results showed satisfaction with the distribution of the item responses to the full EORTC questionnaire provided to the participants to gauge symptoms across the conditions, and that the items were “very much” relevant to CLL/SLL and MCL.
Overall, the participants indicated that the items presented were able to accurately describe the range of symptom severity experienced, the investigators found. Furthermore, the items were deemed to be sufficiently targeted to the study participants.
“The flexibility of adding additional targeted items to capture aspects of disease and treatment not previously considered allows researchers to collect a more nuanced assessment of patient experience,” the investigators wrote.
Some limitations of the study were acknowledged by the study authors. The study relied on patient-reported diagnoses, and the study population was mostly non-Hispanic and White, which limits the generalizability of the findings.
The investigators concluded by discussing the preliminary nature of the findings and determined that the PRO measures resulting from this research should undergo further evaluation in larger cohorts to better understand the benefits for the affected populations.
Reference
Markowitz JT, Mazerolle F, Lovell T, et al. Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library. J Patient Rep Outcomes. 2024;8(1):8. doi:10.1186/s41687-024-00683-2
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More